Financial Perspectives, Inc Aridis Pharmaceuticals, Inc. Transaction History

Financial Perspectives, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jan 09, 2024	SELL	$0.07 - $0.35 $17 - $87	-250 Closed	0 $0
Q2 2021 Jan 09, 2024	SELL	$5.3 - $7.4 $6,492 - $9,065	-1,225 Reduced 83.05%	250 $1.85 Million
Q1 2021 Jan 09, 2024	BUY	$5.54 - $8.1 $6,786 - $9,922	1,225 Added 490.0%	1,475 $250,000
Q2 2020 Jan 09, 2024	BUY	$5.24 - $8.97 $1,310 - $2,242	250 New	250 $1.66 Million

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Perspectives, Inc with notifications on news.